PEPTIDEREPORT

FDA · Agency statement

FDA announces intent to act against mass-marketed non-approved compounded GLP-1 drugs

FDA announced intended enforcement steps involving GLP-1 active pharmaceutical ingredients used in mass-marketed non-approved compounded drugs and misleading direct-to-consumer promotion. The statement named Hims & Hers among the companies in scope but was not itself a final adjudication against that company.

Intent announced legal stageFeb 6, 2026 record dateUnited States jurisdiction
Open the primary-source record

Record status

Policy statement

Agency
U.S. Food and Drug Administration
Action
Enforcement policy statement
Stage
Intent announced
Last verified
Jul 10, 2026

Source-backed timeline

Status history

  1. Enforcement intent announcedSource

Editorial boundary: Peptide Report summarizes the public source and preserves its procedural stage. This page does not convert an allegation, proposal, advisory discussion, or warning into a final legal conclusion.

Back to all Regulatory Watch records